Kangmei Pharmaceutical Hits Day Low of CNY 1.44 Amid Price Pressure

Kangmei Pharmaceutical Co., Ltd. experienced a notable decline today, with the stock dropping by 3.97% on June 8, 2026. The stock reached an intraday low of CNY 1.44, reflecting ongoing challenges in its financial performance. Over the past week, Kangmei has seen a decrease of 6.45%, while its monthly performance shows a significant drop of 14.71%. In the context of the broader market, the China Shanghai Composite index fell by 1.7% today, indicating that Kangmei's decline is more pronounced compared to the overall market trend. Over the past year, the stock has underperformed dramatically, with a loss of 25.64%, contrasting sharply with the 16.95% gain of the Shanghai Composite. Financial metrics reveal a concerning picture for Kangmei, with net profit plummeting by 256.66% in the latest quarter. The company's return on equity stands at a low of 0.17%, and it has a price-to-book ratio of 2.71. These figures highlight the ongoing difficulties faced by Kangmei Pharmaceutical in maintaining a competitive position within the pharmaceuticals and biotechnology industry.